HCW Biologics Inc.

HCWB • Biotechnology

$2.94

▲ +0.07 (+2.44%)

Current price

EarningsLatest report: Jun 30, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$3.90M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

High debt level · 2.46Weak liquidity · 0.11Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:24 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$2.94

Change2.44%

Shares Out1.33M

Market Cap$3.90M

Enterprise Value$9.72M

52W Range1.50 - 44.10

Beta2.36

P/E-0.26

P/S0.58

P/B0.53

P/FCF-0.32

EV/Sales1.45

Price$2.94

Change2.44%

Shares Out1.33M

Market Cap$3.90M

Enterprise Value$9.72M

52W Range1.50 - 44.10

Beta2.36

P/E-0.26

P/S0.58

P/B0.53

P/FCF-0.32

EV/Sales1.45

EV/EBITDA-3.33

EV/FCF-0.80

Earnings Yield-386.15%

FCF Yield-310.86%

Dividend Yield0.00%

Gross Margin20.00%

Oper. Margin-207.58%

Profit Margin-146.77%

Debt/Eq2.46

Current Ratio0.11

Quick Ratio0.11

Volume129.28K

Avg Volume2.05M

EPS Surprise0.81

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

20/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

58/100

Why this score▼

High debt level · 2.46Weak liquidity · 0.11Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

HCWB

Analyst sentiment

Based on 3 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Company Overview

IPO: 7/20/2021

Industry: Biotechnology

P/B i: 0.53

Debt / Equity i: 2.46

Operating Margin: -20757.65%

Net Margin: -14677.14%

ROE i: -

ROIC: -

Financial Health

Score4 / 20

Debt / Equity: 2.46

Current Ratio: 0.11

Quick Ratio: 0.11

Status: HighRisk

Warnings

High debt level
Weak Liquidity
Weak quick ratio

Insider Transactions

Recent executive and insider activity

GARRETT SCOTT T

Transaction: 07/29/2026

BUY

Change

+7,736

Price

$2.58

Filing

07/31/2026

Type

BUY

Flowers Lee

Transaction: 07/29/2026

BUY

Change

+7,736

Price

$2.58

Filing

07/31/2026

Type

BUY

Wong Hing C

Transaction: 07/29/2026

BUY

Change

+23,210

Price

$2.58

Filing

07/31/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
GARRETT SCOTT T	BUY	+7,736	$2.58	07/29/2026	07/31/2026
Flowers Lee	BUY	+7,736	$2.58	07/29/2026	07/31/2026
Wong Hing C	BUY	+23,210	$2.58	07/29/2026	07/31/2026
Byam Rebecca	BUY	+14,235	$1.28	05/22/2026	05/27/2026
Byam Rebecca	BUY	+14,235	$1.41	05/22/2026	05/27/2026
GARRETT SCOTT T	BUY	+177,936	$1.28	05/22/2026	05/27/2026
GARRETT SCOTT T	BUY	+177,936	$1.41	05/22/2026	05/27/2026
Wong Hing C	BUY	+113,879	$1.28	05/22/2026	05/27/2026
Wong Hing C	BUY	+113,879	$1.41	05/22/2026	05/27/2026
GARRETT SCOTT T	BUY	+13,423	$7.45	05/16/2025	05/20/2025
Winer Gary M	BUY	+1,342	$7.45	05/16/2025	05/20/2025
Wong Hing C	BUY	+8,054	$7.45	05/16/2025	05/20/2025
Greene Rick S.	BUY	+962	$26.00	05/08/2025	05/09/2025
Flowers Lee	BUY	+962	$26.00	05/08/2025	05/09/2025
Byam Rebecca	BUY	+8,462	$26.00	05/08/2025	05/09/2025
GARRETT SCOTT T	BUY	+5,385	$26.00	05/08/2025	05/09/2025
Wong Hing C	BUY	+92,500	$26.00	05/08/2025	05/09/2025
Winer Gary M	BUY	+2,308	$26.00	05/08/2025	05/09/2025
Greene Rick S.	BUY	+481	$26.00	05/07/2025	05/09/2025
Flowers Lee	BUY	+481	$26.00	05/07/2025	05/09/2025

About the Company

HCW Biologics Inc.

HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.

Source - link

Peers

ACXP ADIL APRE APVO BCDA BCLI CELZ INAB NRSN RNAZ

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment

HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells Patent allowance received for use of HCW9302 as treatment for alopecia areata Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata on track for completion in Q4 2026, continues to be well tolerated with no dose-limiting toxicities Preliminary readout of first two dose cohorts is encouraging -- patients diagnosed with alopecia areata show positive response after single dose of monotherapy at 3 micrograms/kg dose level MIRAMAR, Fla., Sept. 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for claims directed to use of HCW9302 to treat alopecia areata (U.S. Patent Application Publication No.

GlobeNewsWire

HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8 + T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research institutions, have identified a TGF-β trap and IL-15 fusion as a novel moiety with potential applications against diseased cells and viral infections.

GlobeNewsWire

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and six months ended June 30, 2026.

GlobeNewsWire

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.6 million private placement offering (the “Offering”) with a group of investors, including officers, directors and an existing stockholder of the Company, (each, and “Investor” and collectively, the “Investors”). Pursuant to a securities purchase agreement entered into with the Investors (the “Purchase Agreement”), the Company agreed to issue and sell an aggregate of 618,682 units (the “Units”), with each Unit consisting of (i) one share of the Company's common stock, par value $0.0001 per share (“Common Stock”), or, in lieu thereof, one pre-funded warrant to purchase one share of Common Stock (a “Pre-Funded Warrant”), and (ii) the right to receive one common stock purchase warrant (a “Common Warrant”) to purchase one share of Common Stock upon, and subject to, stockholder approval of the issuance thereof.

GlobeNewsWire

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

Company requested Type B pre-IND meeting with U.S. FDA to discuss development and regulatory strategy for its investigational tetravalent T-cell engager, HCW11-018b HCW11-018b has demonstrated potential for treating solid tumors that overexpress human tissue factor, including gynecologic and pancreatic cancers Company has developed a streamlined, robust manufacturing process designed to produce high-quality cGMP material at a lower cost than current methods MIRAMAR, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today announced that it has requested a Type B (pre-IND application) meeting with the U.S. FDA to discuss the development and regulatory strategy for its investigational lead product candidate, HCW11-018b, a tetravalent T-cell engager (“TCE”) constructed with the Company's proprietary TRBC drug development platform.

GlobeNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-14	-0.44	0.37	0.81
2026-03-31	-0.84	-2.63	-1.79
2025-11-14	1.58	-2.02	-3.6
2025-08-18	1.8	-6.79	-8.59
2025-03-28	3.6	-3.2	-6.8
2024-11-14	-5.2	-4	1.2
2024-08-14	-7.2	-16	-8.8
2023-11-14	-0.13	-5.6	-5.47
2023-08-11	-0.15	-4.8	-4.65
2023-05-09	-0.14	-5.6	-5.46
2023-03-28	-0.16	-6	-5.84
2022-11-07	-0.12	-5.6	-5.48